Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China -January 09, 2024 at 10:22 pm EST
- Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta monoclonal antibody LEQEMBI has been approved in China as a treatment of mild cognitive...